An official website of the United States government
Poverty and Cancer Disparities in Ohio
ORIGINAL RESEARCH — Volume 15 — December 6, 2018
PEER REVIEWED
Figure 1. Ratios comparing cancer incidence rates in the 12 poorest counties with cancer incidence rates in the 10 most affluent counties in Ohio, by site or type of cancer, 2011–2015. Rates are per 100,000, age-adjusted to the 2000 US standard population and sex-specific for breast, cervix, ovary, prostate, testis, and uterus. Types of cancer were categorized according to the conventions of the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program (11). Source of data on incidence: Ohio Department of Health (9).
| Site or Type of Cancer | Rate Ratio (95% Confidence Interval) |
|---|---|
| Cervix | 1.8 (1.44–2.16) |
| Larynx | 1.4 (1.16–1.67) |
| Esophagus | 1.3 (1.14–1.56) |
| Liver and intrahepatic bile duct | 1.2 (1.08–1.43) |
| Lung and bronchus | 1.2 (1.15–1.26) |
| Oral cavity and pharynx | 1.2 (1.07–1.32) |
| Colon and rectum | 1.1 (1.07–1.19) |
| Multiple myeloma | 1.1 (0.91–1.22) |
| Stomach | 1.0 (0.89–1.20) |
| Bladder | 1.0 (0.94–1.10) |
| All sites | 1.0 (0.99–1.02) |
| Uterus | 1.0 (0.91–1.09) |
| Kidney and renal pelvis | 1.0 (0.90–1.07) |
| Pancreas | 1.0 (0.88–1.08) |
| Leukemia | 1.0 (0.88–1.07) |
| Prostate | 0.9 (0.88–0.98) |
| Breast (female) | 0.9 (0.87–0.95) |
| Brain and other central nervous system | 0.9 (0.78–1.04) |
| Non-Hodgkin lymphoma | 0.9 (0.80–0.95) |
| Ovary | 0.9 (0.74–0.99) |
| Thyroid | 0.8 (0.77–0.93) |
| Hodgkin lymphoma | 0.8 (0.62–1.00) |
| Testis | 0.8 (0.61–0.99) |
| Melanoma of the skin | 0.7 (0.67–0.79) |
Figure 2. Ratios comparing cancer mortality rates in the 12 poorest counties with cancer mortality rates in the 10 most affluent counties in Ohio, by site or type of cancer, 2011–2015. Rates are per 100,000, age-adjusted to the 2000 US standard population and sex-specific for breast, cervix, ovary, prostate, testis, and uterus. Types of cancer were categorized according to the conventions of the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program (11). Source of data on mortality: Ohio Department of Health (13).
| Site or Type of Cancer | Rate Ratio (95% Confidence Interval) |
|---|---|
| Larynx | 2.3 (1.6–3.1) |
| Cervix | 2.3 (1.6–3.2) |
| Thyroid | 1.5 (0.9–2.5) |
| Oral cavity and pharynx | 1.4 (1.1–1.7) |
| Liver and intrahepatic bile duct | 1.4 (1.2–1.6) |
| Colon and rectum | 1.3 (1.2–1.5) |
| Prostate | 1.3 (1.1–1.5) |
| Lung and bronchus | 1.3 (1.2–1.3) |
| All sites | 1.2 (1.2–1.2) |
| Esophagus | 1.2 (1.0–1.4) |
| Bladder | 1.1 (1.0–1.3) |
| Kidney and renal pelvis | 1.1 (0.9–1.3) |
| Multiple myeloma | 1.1 (0.9–1.3) |
| Stomach | 1.1 (0.9–1.4) |
| Leukemia | 1.1 (0.9–1.2) |
| Non-Hodgkin lymphoma | 1.1 (0.9–1.2) |
| Pancreas | 1.1 (0.9–1.2) |
| Uterus | 1.0 (0.8–1.3) |
| Brain and other central nervous system | 1.0 (0.8–1.2) |
| Breast (female) | 1.0 (0.9–1.1) |
| Ovary | 0.9 (0.8–1.1) |
| Melanoma of the skin | 0.9 (0.7–1.1) |
| Testis | 0.8 (0.3–1.8) |
| Hodgkin lymphoma | 0.7 (0.3–1.4) |
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.